According to FutureWise analysis, the single-use bioprocessing market in 2025 is US$32.11 billion, and is expected to reach US$70.09 billion by 2033 at a CAGR of 10.25%. The single-use bioprocessing market is experiencing significant growth, largely due to the increasing adoption of disposable technologies in biopharmaceutical manufacturing. These technologies offer greater flexibility and reduce the risk of contamination. Additionally, the rising demand for biologics and biosimilars, along with the need for cost-effective and time-efficient production processes, is further driving market expansion. Currently, North America leads the single-use bioprocessing market, while the Asia-Pacific region is emerging as a high-growth area, thanks to improvements in pharmaceutical infrastructure and increased investment in bioprocessing capabilities. The growth in this sector is primarily driven by the increasing adoption of biologics and biosimilars, which require scalable and contamination-free production methods. Single-use systems provide operational flexibility, lower cleaning and validation costs, and faster turnaround times for small- to mid-scale bioproduction. Their growing use in cell and gene therapy manufacturing, where maintaining sterility and ensuring batch-to-batch consistency are critical, is also contributing to the expansion of the market.

Single-use bioprocessing, often referred to as disposables, is transforming the pharmaceutical landscape with innovative solutions designed for efficiency and safety. Imagine a world where products like media bags, filtration assemblies, and disposable bioreactors are only used once and then effortlessly discarded—simplifying the bioprocessing experience!These versatile tools are instrumental in a wide array of applications, from the production of life-saving monoclonal antibodies and vaccines to the cultivation of plant cells and advanced cell therapies. By embracing single-use technologies, biopharmaceutical companies and life science research organizations can significantly boost productivity while minimizing the risk of cross-contamination. It’s a game-changing approach that not only streamlines operations but also enhances the quality of pharmaceutical products. Welcome to the future of bioprocessing!

FutureWise Market Research has instantiated a report that provides an intricate analysis of Single-use Bioprocessing Market trends that shall affect the overall market growth.

Request a Free Sample @

https://www.futurewiseresearch.com/contact.aspx?rpt=10062&type=requestsample

By Product

• Media Bags and Containers
• Filtration Assemblies
• Single-use Bioreactors
• Disposable Mixers
• Others

By End User

• Academic and Clinical Research Institutes
• Biopharmaceutical Manufacturers

By Application

• Filtration
• Chromatography
• Membrane Filtration
• Refining and Separation
• Storage
• Cell Culture
• Purification

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape in Single-use Bioprocessing Market:

• Thermo Fisher Scientific Inc.
• GE Healthcare
• Sartorius Stedim Biotech S.A.
• Merck Millipore
• Danaher Corporation
• 3M Company
• Eppendorf AG
• Hamilton Company
• Corning Incorporated
• Cesco Bioengineering Co., Ltd.

Recent developments by key players in the Single-use Bioprocessing Market:

Thermo Fisher Scientific Inc.

• In June 2024, plant-based, lower-carbon films were launched for its Aegis and CX single-use container lines as part of a broader sustainability initiative. These bio-based films reduce environmental impact while maintaining performance quality.
• Significantly scales production capacity at its Nashville and Ogden sites, which together support a massive output of containers, bags, sensors, and downstream consumables for biopharma and vaccine manufacturing.
• In February 2025, a planned acquisition of Solventum’s purification and filtration unit for $4.1 billion was announced, enabling the expansion of its filtration technology into integrated systems with bioprocessing capabilities.

Danaher Corporation

• In May 2023, the merger of Cytiva and Pall Life Sciences was completed, forming a large, vertically integrated group within Danaher focused on single-use solutions to support end-to-end biologics production.
• In April 2024, the Xcellerex magnetic mixer was introduced for 2,000–3,000 L single-use bioreactors, designed to enhance the manufacturing of mAb, vaccines, and gene therapies with improved mixing efficiency.

Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=10062&license=multi

**Objectives of this Study: **

1. To provide a comprehensive analysis of the Single-use Bioprocessing Market By Product, By End User, By Application and By Region.
2. To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
3. To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
4. To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

                                                                                                                
Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
• The customization services offered are free of charge with the purchase of any license of the report.
• You can directly share your requirements/changes to the current table of contents to: sales@futurewiseresearch.com